A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Study Identifier:
D7841C00008
ClinicalTrials.gov Identifier:
NCT05780645
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN2050 MR Prototype Tablet
  • Drug: ALXN2050 Immediate Release (IR) Tablet
  • Drug: ALXN2050 MR Prototype Mini-Tablet
Date
Mar 2023 - Feb 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN2050 MR Prototype Tablet
  • Drug: ALXN2050 Immediate Release (IR) Tablet
  • Drug: ALXN2050 MR Prototype Mini-Tablet
Date
Mar 2023 - Feb 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

The primary objectives of this study are to investigate the relative bioavailability and PK (Pharmacokinetic) profile of 2 ALXN2050 MR (Modified Release) formulations in comparison with the IR (Immediate Release) formulation.

Trial Locations

Location
Status
Location
Research Site
Ruddington, United Kingdom, NG11 6JS
Status
N/A